More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

mRNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its 2025 ...

Moderna stock has been under pressure amid declining sales of its COVID-19 vaccine. The company projects ... in clinical trials that could be the booster shot the stock needs to generate a rebound.

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...

The biotech, renowned for its pioneering development of vaccines ... could be the booster shot the stock needs to generate a rebound. It's been more than four years since Moderna rose to ...